{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:03:55Z","timestamp":1789419835149,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"crossref","award":["3629"],"award-info":[{"award-number":["3629"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.yebeh.2013.07.006","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T20:53:26Z","timestamp":1377204806000},"page":"150-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: A pilot study"],"prefix":"10.1016","volume":"29","author":[{"given":"Ali A.","family":"Asadi-Pooya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Mohammad Ali","family":"Razavizadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Abdi-Ardekani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2013.07.006_bb0005","first-page":"S1","article-title":"The modern challenges of drug resistant epilepsy","volume":"7","author":"Ryvlin","year":"2005","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.seizure.2013.01.010","article-title":"Reasons for uncontrolled seizures in adults; the impact of pseudointractability","author":"Asadi-Pooya","year":"2013","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2013.07.006_bb0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.yebeh.2012.08.015","article-title":"Reasons for uncontrolled seizures in children; the impact of pseudointractability","volume":"25","author":"Asadi-Pooya","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/pgmj.2004.019976","article-title":"New drugs for the treatment of epilepsy: a practical approach","volume":"80","author":"Beyenburg","year":"2004","journal-title":"Postgrad Med J"},{"issue":"1","key":"10.1016\/j.yebeh.2013.07.006_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1528-1167.2006.00377.x","article-title":"Refractory generalized seizures: response to corpus callosotomy and vagal nerve stimulation","volume":"47","author":"Nei","year":"2006","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2013.07.006_bb0030","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1528-1167.2005.54904.x","article-title":"Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms","volume":"46","author":"Schmidt","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2013.07.006_bb0035","first-page":"S3","article-title":"Mechanisms of drug resistance","volume":"7","author":"Loscher","year":"2005","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1995.tb01657.x","article-title":"MDR 1 gene expression in brain of patients with medically intractable epilepsy","volume":"36","author":"Tishler","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-2-37","article-title":"Significance of MDR 1 and multiple drug resistance in refractory human epileptic brain","volume":"2","author":"Marchi","year":"2004","journal-title":"BMC Med"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0050","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.neuroscience.2003.10.012","article-title":"Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures","volume":"123","author":"Volk","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/brain\/awf002","article-title":"Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy","volume":"125","author":"Sisodiya","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0060","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1345\/aph.1E068","article-title":"Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy","volume":"38","author":"Summers","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.yebeh.2013.07.006_bb0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1535-7511.2005.05311.x","article-title":"How to explain multidrug resistance in epilepsy?","volume":"5","author":"Loscher","year":"2005","journal-title":"Epil Current"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0070","series-title":"AHFS drug information","first-page":"1890","year":"2006"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0075","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0006-3223(01)01338-5","article-title":"Verapamil treatment for women with bipolar disorder","volume":"51","author":"Wisner","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0080","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/070674379904400702","article-title":"Calcium channel blockers in psychiatric disorders: a review of the literature","volume":"44","author":"Hollister","year":"1999","journal-title":"Can J Psychiatry"},{"issue":"2 Suppl. 2","key":"10.1016\/j.yebeh.2013.07.006_bb0085","first-page":"S1","article-title":"Canadian Headache Society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim","year":"2012","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.12.007","article-title":"Inhibition of multidrug transporters by verapamil or probenecid does not alter blood\u2013brain barrier penetration of levetiracetam in rats","volume":"58","author":"Potschka","year":"2004","journal-title":"Epilepsy Res"},{"issue":"18","key":"10.1016\/j.yebeh.2013.07.006_bb0095","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.yebeh.2013.07.006_bb0100","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/01.wnl.0000259034.45049.00","article-title":"Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures","volume":"68","author":"Porter","year":"2007","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.yebeh.2013.07.006_bb0105","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1212\/WNL.0b013e31826d5ec0","article-title":"Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review","volume":"79","author":"Pellock","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2013.07.006_bb0110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1528-1157.1994.tb02513.x","article-title":"Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group","volume":"35","author":"Anhut","year":"1994","journal-title":"Epilepsia"},{"issue":"2\u20133","key":"10.1016\/j.yebeh.2013.07.006_bb0115","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2006.02.004","article-title":"Diverse mechanisms of antiepileptic drugs in the development pipeline","volume":"69","author":"Rogawski","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5698\/1535-7511-11.1.9","article-title":"Efficacy of new antiepileptic drugs","volume":"11","author":"Schmidt","year":"2011","journal-title":"Epilepsy Curr"},{"issue":"3","key":"10.1016\/j.yebeh.2013.07.006_bb0130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.mehy.2006.12.054","article-title":"Potentiation of antiepileptic drugs effectiveness by pyronaridine in refractory epilepsy","volume":"69","author":"Asadi-Pooya","year":"2007","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.yebeh.2013.07.006_bb0135","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/clc.4960141203","article-title":"Calcium antagonists in cardiology: update on sustained-release delivery systems","volume":"14","author":"Michelson","year":"1991","journal-title":"Clin Cardiol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505013003296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505013003296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T18:41:40Z","timestamp":1563734500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505013003296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1525505013003296"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2013.07.006","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2013.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}